Beyond Anticoagulant Exposure: Determinants of Mortality After Gastrointestinal Bleeding Across DOAC , Warfarin and Non‐Anticoagulated Patients
Alimentary Pharmacology & Therapeutics · 22.10.2026
DOI: 10.1111/apt.71063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 22.10.2026. Verfasst von Esther Forkosh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Gastroenterology and Hepatology, Hadassah Medical Center, and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Aims Reported outcomes after gastrointestinal bleeding (GIB) in anticoagulated patients are inconsistent, and comparisons with non‐anticoagulated patients are limited. We assessed whether anticoagulation status was independently associated with mortality after GIB and identified predictors of death.
Methods
We analysed 11,387 consecutive adults with acute GIB over 25 years ( n = 500 direct oral anticoagulant [DOAC], n = 353 warfarin, n = 10,534 non‐anticoagulated). All‐cause mortality at 30 days and 1 year was modelled using overlap‐weighted logistic regression, with complete mortality follow‐up through the Israeli National Population Registry.
Results
Anticoagulated patients were older (median age 81.7 [DOAC] and 75.1 [warfarin] vs. 58.4 years), had greater comorbidity and higher crude mortality than non‐anticoagulated patients. After overlap weighting, neither DOAC nor warfarin was significantly associated with mortality (30‐day OR 1.61, 95% CI 0.81–3.21 for DOAC and 1.30, 95% CI 0.56–3.02 for warfarin; 1‐year OR 0.90, 95% CI 0.62–1.31 and 1.08, 95% CI 0.69–1.69). At 30 days, mortality was associated with age, haemodynamic shock (OR 4.25) and Internal Medicine ward admission (OR 4.55); at 1 year, with age, renal failure, Internal Medicine ward admission and inversely with male sex. Anticoagulation was resumed at discharge in 37.8% of survivors.
Conclusions
Neither DOAC nor warfarin was significantly associated with 30‐day or 1‐year mortality after GIB, including when bleeding severity and admitting ward were excluded from the outcome model. Thirty‐day mortality was associated with severity at presentation, whereas 1‐year mortality was associated with underlying patient characteristics. Resumption was not significantly associated with mortality or readmission for recurrent bleeding.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Gastroenterology and Hepatology, Hadassah Medical Center, and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
- Ellen and Pinchas Mamber Institute of Gastroenterology and Hepatology, Emek Medical Center, Afula, Israel.
- Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Center, and Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
ORCID-Profile: Esther Forkosh, Lior Katz
Zitieren
APA
Forkosh, E., Hakimian, D., Jacob, H., Gralnek, I. M., Katz, L., & Talmon, A. (2026). Beyond Anticoagulant Exposure: Determinants of Mortality After Gastrointestinal Bleeding Across DOAC , Warfarin and Non‐Anticoagulated Patients. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71063
Vancouver
Forkosh E, Hakimian D, Jacob H, Gralnek IM, Katz L, Talmon A. Beyond Anticoagulant Exposure: Determinants of Mortality After Gastrointestinal Bleeding Across DOAC , Warfarin and Non‐Anticoagulated Patients. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71063
BibTeX
@article{Forkosh2026,
author = {Forkosh, Esther and Hakimian, David and Jacob, Harold and Gralnek, Ian M and Katz, Lior and Talmon, Aviv},
title = {Beyond Anticoagulant Exposure: Determinants of Mortality After Gastrointestinal Bleeding Across DOAC , Warfarin and Non‐Anticoagulated Patients},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.71063}
}
EUVIMED